Quantum Leap Healthcare Collaborative
search

Meeting Abstracts

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.

I-SPY at 2019 SABCS

Please check again soon!

2019

Li W, Onishi N, Newitt DC, et al.
The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P6-02-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Venters SJ, Wolf DM, Brown-Swigart L, et al.
Assessing biomarkers to inform treatment de-escalation: mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P6-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Pohlmann PR, Yau C, DeMichele A, et al.
Amsterdam 70-gene profile (MammaPrint) Low Risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P6-10-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua MM, Brown-Swigart L, Hirst G, et al.
Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in highrisk early stage breast cancer reflects response and risk of metastatic recurrence
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P5-01-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Ghersin H, Chattopadhyay A, Blaes A, et al.
Introducing an electronic platform to collect patient reported outcomes in the I-SPY 2 TRIAL, a neoadjuvant clinical trial
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
OT3-19-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, van der Noordaa M, Wei J, et al.
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
GS5-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Sayaman RW, Wolf DM, Yau C, et al.
Application of Machine Learning to elucidate the biology predicting response in the I‑SPY 2 neoadjuvant breast cancer trial
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P1-21-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkuhle J, et al.
HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P4-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Onishi N, Li W, Newitt DC, et al.
Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
PD9-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Onishi N, Newitt DC, et al.
Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
PD9-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Arasu V, Kim P, Li W, et al.
Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in I-SPY2
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
PD9-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Osdoit M, Yau C, Symmans WF, et al.
The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P3-08-16
.
abstract
doi link
poster (pdf)
slides (pdf)
Helsten TL, Lo SS, Yau C, et al.
Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P3-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Liu MC, Robinson PA, Yau C, et al.
Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: Results from the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P3-09-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Basu A, Philip EJ, Dewitt B, et al.
The Clinical Benefit Index: A Pilot Study Integrating Treatment Efficacy and Quality of Life in Oncology Clinical Trials
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P2-12-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Du L, Yau C, Brown-Swigart L, et al.
Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2- negative (HR+/HER2-) breast cancer
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P2-11-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Symmans W, Pusztai L, et al.
Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints
.
2019 San Antonio Breast Cancer Symposium
December 10-14
2019
. In: 
;
 (
)
; Abstract No. 
P2-20-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Campbell MJ, Yau C, Bolen J, et al.
Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
.
AACR Annual Meeting
Mar 29 - APr 3
2019
. In: 
Cancer Res
2019
;
79
 (
13 Suppl
)
; Abstract No. 
CT003
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Newitt DC, Wilmes LJ, et al
Combination of MRI quantitative measures improves prediction of residual disease following neoadjuvant chemotherapy (NAC) for breast cancer in the I-SPY 2 TRIAL
.
ISMRM 27th Annual Meeting
May 11-16
2019
. In: 
;
 (
)
; Abstract No. 
0278
.
abstract
doi link
poster (pdf)
slides (pdf)
Wulfkuhle JD, Yau C, Wolf D, et al.
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial
.
2019 ASCO Annual Meeting
May 30 - June 4
2019
. In: 
J Clin Oncol
2019
;
37
 (
15
)
; Abstract No. 
2631
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkuhle J, et al.
Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial
.
AACR Annual Meeting 2019
Mar 29 - Apr 3
2019
. In: 
Cancer Res
2019
;
79
 (
13 Suppl
)
; Abstract No. 
2679
.
abstract
doi link
poster (pdf)
slides (pdf)

2018

Hyland C, Varghese F, Yau C, et al.
The use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer reduces false positives, costs, and time to treatment: a multicenter value analysis in the I-SPY2 trial
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P5-15-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Zhu Z, Yau C, van ’t Veer L, et al.
Molecular subtypes of invasive lobular breast cancer in the I-SPY2 Trial
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
PD7-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Wolf D, Campbell M, et al.
Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Brown-Swigart L, Asare S, et al/
LIV-1 Expression in Primary Breast Cancers in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-14
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Newitt DC, Yun BL, et al.
MRI detection of residual disease following neoadjuvant chemotherapy (NAC) in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
PD4-03
.
abstract
doi link
poster (pdf)
slides (pdf)
van der Noordaa MEM, Esserman L, Yau C, et al
Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cN0 patients in the I-SPY 2 trial
.
2018 San Antonio Breast Cancer Symposium
December 4-9
2018
. In: 
;
 (
)
; Abstract No. 
PD4-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Hylton NM, Symmans WF, Yau C, et al.
Refining neoadjuvant predictors of three year distant metastasis free survival: integrating volume change as measured by MRI with residual cancer burden
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P2-07-03
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkhule J, et al.
Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Silverstein J, Suleiman L, Yau C, et al.
The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
December 4-8
2018
. In: 
;
 (
)
; Abstract No. 
P2-14-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua M, Brown-Swigart L, Hirst G, et al
Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
Dec 4-8
2018
. In: 
;
 (
)
; Abstract No. 
PD2-01
.
abstract
doi link
poster (pdf)
slides (pdf)
van 't Veer L, Wolf D, Yau C, et al.
MammaPrint High1/High2 risk class as a pre-specified biomarker of response to nine different targeted agents plus standard neoadjuvant therapy for ~ 1000 breast cancer patients in the I-SPY 2 TRIAL
.
30th EORTC-NCI-AACR Symposium
November 13-16
2018
. In: 
;
 (
)
; Abstract No. 
.
abstract
doi link
poster (pdf)
slides (pdf)
Wulfkuhle JD, Wolf DM, Yau C, et al
Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
12099
.
abstract
doi link
poster (pdf)
slides (pdf)
Gallagher RI, Wulfkuhle JD, Yau C, et al
Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
12103
.
abstract
doi link
poster (pdf)
slides (pdf)
Fraser Symmans W, Yau C, Chen Y, et al
Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
. In: 
J Clin Oncol
2018
;
36 suppl
 (
)
; Abstract No. 
520
.
abstract
doi link
poster (pdf)
slides (pdf)
William Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al
Advances in Precision Medicine in Triple-Negative Breast Cancer: Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL Poster Presentation
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
520
.
abstract
doi link
poster (pdf)
slides (pdf)
Lee PRE, Zhu Z, Wolf D, et al
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients
.
2018 AACR Annual Meeting
April 14-18
2018
. In: 
Cancer Res
2018
;
78
 (
13 Suppl
)
; Abstract No. 
2612
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Brown-Swigart L, et al
Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 86) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer
.
2018 AACR Annual Meeting
April 14-18
2018
. In: 
Cancer Res
2018
;
78
 (
13 Suppl
)
; Abstract No. 
2611
.
abstract
doi link
poster (pdf)
slides (pdf)

2017

Campbell M, Yau C, Borowsky A, et al.
Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
Dec 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl
)
; Abstract No. 
PD6-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Yee D, DeMichele A, Isaacs C, et al.
Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
.
2017 San Antonio Breast Cancer Symposium
Dec 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl
)
; Abstract No. 
GS3-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Nanda R, Liu MC, Yau C, et al.
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
.
2017 American Society of Clinical Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
506
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Wolf D, Brown-Swigart L, et al.
Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
PD6-14
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Wilmes LJ, Newitt DC, et al.
Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
P2-09-23
.
abstract
doi link
poster (pdf)
slides (pdf)
Pradhan SM, Carey L, Edmiston S, et al.
P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657)
.
2017 American Society of Clinical Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
)
; Abstract No. 
11099
.
abstract
doi link
poster (pdf)
slides (pdf)
Partridge SC, Zhang Z, Newitt DC, et al.
ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer
.
2017 American Society of Clinical Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
11520
.
abstract
doi link
poster (pdf)
slides (pdf)
Vidula N, Yau C, Rugo HS, et al.
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
.
2017 American Society of Cancer Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
1075
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf D, Yau C, Brown-Swigart L, et al.
Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
P2-09-08
.
abstract
doi link
poster (pdf)
slides (pdf)

2016

Gallagher RI, Yau C, Wolf DM, et al.
Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P3-05-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Vidula N, Yau C, Wolf DM, et al.
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes
.
2016 American Society of Clinical Oncology Annual Meeting
June 3-7
2016
In: 
J Clin Oncol
2016
;
34
 (
15 Suppl.
)
, Abstract No. 
1072
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Sanil A, et al.
Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
858
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Arasu V, Jones EF, et al.
Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes – Results from ACRIN 6657 / I-SPY 1 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
PD3-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Sanil A, et al.
DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
S2-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Shah M, Jensen R, Yau C, et al.
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
)
, Abstract No. 
P5-11-18
.
abstract
doi link
poster (pdf)
slides (pdf)
Yee D, Paoloni M, Van't Veer L, et al.
The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P6-11-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Brown-Swigart L, et al.
Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
859
.
abstract
doi link
poster (pdf)
slides (pdf)
Buxton M, DeMichele AM, Chia S, et al.
Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
CT106
.
abstract
doi link
poster (pdf)
slides (pdf)
DeMichele AM, Moulder S, Buxton M, et al.
Efficacy of T-DM1 + pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
CT042
.
abstract
doi link
poster (pdf)
slides (pdf)
Paoloni M, Lyandres J, Buxton MB, et al.
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P2-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Forero A, Yee D, Buxton MB, et al.
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
)
, Abstract No. 
P6-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
-- view older abstracts --